Positron-emitting radiopharmaceuticals: How safe are they?

Cancer Biotherapy and Radiopharmaceuticals

Volumn 16, Issue 1, 2001, Pages 13-15

  Silberstein, E B ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

CANCER LOCALIZATION; DRUG SAFETY; EDITORIAL; HUMAN; ISOTOPE LABELING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; SCINTILLATION CAMERA; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR VOLUME;

EID: 0035077935     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497801750095943     Document Type: Editorial

References (10)

1. Oncological applications of FDG PET imaging
2. 18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: An overview of different analytical methods
3. PET imaging in oncology
4. Role of repeated F-18 fluorodeoxyglucose imaging in management of patients with bone soft tissue sarcoma
5. Comparison of dual-head coincidence gamma camera FDG imaging with FDG PET in detection of breast cancer and axillary lymph node metastases
6. Prevalence of adverse reactions in nuclear medicine
7. Prevalence of adverse reactions to positron emitting radiopharmaceuticals in nuclear medicine
8. Radiation dose to positron emission tomography technologists during quantitative versus qualitative studies
9. Estimation of absorbed doses in humans due to intravenous administration of fluorine-18-fluorodeoxyglucose in PET studies
10. Are restrictions to behavior of patients required following fluorine-18 fluorodeoxyglucose positron emission tomographic studies?